252578-12-4

Basic information

• Product Name: 2-(4-Boc-AMinopiperidino)pyridine
• Synonyms: 2-(4-Boc-AMinopiperidino)pyridine
• CAS NO: 252578-12-4
• Molecular Formula: C15H23N3O2
• Molecular Weight: 277.36202
• Mol File: 252578-12-4.mol

Chemical Properties

• Boiling Point: 430.3±38.0 °C(Predicted)
• Appearance: /
• Density: 1.12±0.1 g/cm3(Predicted)
• PKA: 12.26±0.20(Predicted)
• CAS DataBase Reference: 2-(4-Boc-AMinopiperidino)pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-Boc-AMinopiperidino)pyridine(252578-12-4)
• EPA Substance Registry System: 2-(4-Boc-AMinopiperidino)pyridine(252578-12-4)

Safety Data

• Hazardous Substances Data: 252578-12-4(Hazardous Substances Data)

Usage

Usage

Intermediate in the synthesis of pharmaceuticals and agrochemicals

Structure

2-(4-Boc-Aminopiperidino)pyridine, with the "2" indicating the position of the pyridine ring and the "4-Boc-Aminopiperidino" portion referring to the substituents on the pyridine ring

Applications

Potential applications in medicinal chemistry and synthetic organic chemistry

Safety precautions

Handle and use with proper safety precautions, as it may be hazardous if not handled properly.

Upstream product

• 109-09-1 2-chloropyridine 
• 73874-95-0 (piperidin-4-yl)carbamic acid tert-butyl ester 
• 109-04-6 2-bromo-pyridine 

Downstream Products

• 144465-94-1 4-amino-1-(pyridin-2-yl)piperidine 

Relevant articles and documents

4- (4-CYANOPHENYL) -1- (3-TRIFLUOROMETHYLPHENYL) -3,4, 6, 7-TETRAHYDRO-1H-PYRROLO [3, 4- D] PYRIMIDINE-2, 5-DIONE DERIVATIVES AND THEIR USE AS HUMAN NEUTROPHIL ELASTASE INHIBITORS

Thirty six specific compounds having human neutrophil elastase inhibitory activity are disclosed, one of which has the structural formula (1). The compounds are useful inter alia for the treatment of inflammatory respiratory disease, and may be administer

NON-ANILINIC DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS

The present invention relates to certain novel compounds of the formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α (NR1H3) and/or β (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.

PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV)

The present invention relates to compounds which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases.